Wall Street brokerages predict that Ionis Pharmaceuticals Inc (NASDAQ:IONS) will post ($0.06) earnings per share for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Ionis Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.36) and the highest estimate coming in at $0.29. Ionis Pharmaceuticals posted earnings of $0.21 per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 128.6%. The business is scheduled to issue its next earnings report on Tuesday, February 27th.
According to Zacks, analysts expect that Ionis Pharmaceuticals will report full-year earnings of ($0.06) per share for the current financial year, with EPS estimates ranging from ($0.25) to $0.22. For the next year, analysts forecast that the firm will post earnings of $0.40 per share, with EPS estimates ranging from ($1.10) to $2.91. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that follow Ionis Pharmaceuticals.
Several equities analysts have recently commented on IONS shares. BidaskClub upgraded Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, December 7th. Zacks Investment Research lowered Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, November 9th. BMO Capital Markets reiterated an “outperform” rating and set a $69.00 price objective on shares of Ionis Pharmaceuticals in a research report on Monday, October 2nd. Needham & Company LLC reiterated a “buy” rating and set a $64.00 price objective on shares of Ionis Pharmaceuticals in a research report on Tuesday, October 17th. Finally, Goldman Sachs Group reiterated a “sell” rating and set a $30.00 price objective on shares of Ionis Pharmaceuticals in a research report on Friday, October 6th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $50.76.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. grew its position in Ionis Pharmaceuticals by 4.4% during the 2nd quarter. Vanguard Group Inc. now owns 9,855,160 shares of the company’s stock worth $501,332,000 after acquiring an additional 417,364 shares during the last quarter. BlackRock Inc. lifted its holdings in Ionis Pharmaceuticals by 4.0% in the 2nd quarter. BlackRock Inc. now owns 6,823,987 shares of the company’s stock worth $347,135,000 after buying an additional 264,179 shares during the period. American Century Companies Inc. lifted its holdings in Ionis Pharmaceuticals by 33.0% in the 3rd quarter. American Century Companies Inc. now owns 1,144,526 shares of the company’s stock worth $58,027,000 after buying an additional 284,266 shares during the period. First Trust Advisors LP lifted its holdings in Ionis Pharmaceuticals by 40.2% in the 3rd quarter. First Trust Advisors LP now owns 982,344 shares of the company’s stock worth $49,805,000 after buying an additional 281,733 shares during the period. Finally, Northern Trust Corp lifted its holdings in Ionis Pharmaceuticals by 7.8% in the 2nd quarter. Northern Trust Corp now owns 621,816 shares of the company’s stock worth $31,631,000 after buying an additional 44,750 shares during the period. Institutional investors and hedge funds own 91.40% of the company’s stock.
Ionis Pharmaceuticals (IONS) opened at $50.22 on Friday. The company has a current ratio of 6.25, a quick ratio of 6.21 and a debt-to-equity ratio of 1.50. The company has a market capitalization of $6,250.00, a PE ratio of 358.71 and a beta of 2.86. Ionis Pharmaceuticals has a 1 year low of $37.26 and a 1 year high of $65.51.
COPYRIGHT VIOLATION NOTICE: This article was reported by American Banking News and is owned by of American Banking News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://www.americanbankingnews.com/2018/01/20/ionis-pharmaceuticals-inc-ions-expected-to-announce-earnings-of-0-06-per-share.html.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.